Expert Review of Vaccines (Dec 2023)

Microarray patches: scratching the surface of vaccine delivery

  • Jovin J. Y. Choo,
  • Christopher L. D. McMillan,
  • Paul R. Young,
  • David A. Muller

DOI
https://doi.org/10.1080/14760584.2023.2270598
Journal volume & issue
Vol. 0, no. 0

Abstract

Read online

Introduction Microneedles are emerging as a promising technology for vaccine delivery, with numerous advantages over traditional needle and syringe methods. Preclinical studies have demonstrated the effectiveness of MAPs in inducing robust immune responses over traditional needle and syringe methods, with extensive studies using vaccines targeted against different pathogens in various animal models. Critically, the clinical trials have demonstrated safety, immunogenicity and patient acceptance for MAP-based vaccines against influenza, measles and rubella, and SARS-CoV-2. Areas covered This review provides a comprehensive overview of the different types of microarray patches (MAPs) and analyses of their applications in preclinical and clinical vaccine delivery settings. This review also covers additional considerations for microneedle-based vaccination, including adjuvants that are compatible with MAPs, patient safety and factors for global vaccination campaigns. Expert opinion MAP vaccine delivery can potentially be a game-changer for vaccine distribution and coverage in both high-income and low or middle-income countries. For MAPs to reach this full potential, many critical hurdles must be overcome, such as large-scale production, regulatory compliance, and adoption by global health authorities. However, given the considerable strides made in recent years by MAP developers, it may be possible to see the first MAP-based vaccines in use within the next 5 years.

Keywords